Search

Methods of Treatment and/or Prevention of Disorders and Symptoms Related to BKCa and/or SK Channelopathies

USPTO granted patent US12605367B2 on April 21, 2026, covering compounds and compositions for treating neurological and non-neurological channelopathies caused by defects in calcium-activated potassium channels. The patent lists 14 claims targeting conditions including Fragile X Syndrome, autism spectrum disorders, Angelman syndrome, and other neuropathic and neurodegenerative diseases. The filing date was September 15, 2020, with application number 17760612.